Diadexus, Inc.

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2021	Diadexus, Inc. Went Out of Business	CI
2018	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016

April 29, 2016 at 06:46 pm EDT

Diadexus, Inc. reported unaudited earnings results for the first quarter ended March 31, 2016. For the quarter, the company reported total revenues of USD 3.532 million compared to USD 5.527 million a year ago. Loss from operations was USD 1.265 million compared to USD 0.508 million a year ago.

Loss before interest income was USD 1.682 million compared to USD 0.959 million a year ago. Net loss was USD 1.688 million compared to USD 0.970 million a year ago. Basic &diluted net loss per share was USD 0.41 compared to USD 0.26 a year ago.

Latest news about Diadexus, Inc.

Diadexus, Inc. Went Out of Business	21-09-17	CI
Motion for Asset Sale Approved for Diadexus, Inc.	18-06-08	CI
Motion for Asset Sale Filed by Diadexus, Inc.	18-05-09	CI
Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	16-07-31	CI
Motion for Asset Sale Approved for Diadexus, Inc.	16-07-29	CI
General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	16-07-28	CI
Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	16-07-19	CI
Motion for Asset Sale Filed by Diadexus, Inc.	16-07-07	CI
Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	16-07-06	CI
Diadexus, Inc. Filed for Bankruptcy	16-06-13	CI
Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	16-06-10	CI
Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	16-05-23	CI
Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	16-04-29	CI
Diadexus, Inc. Provides Revenue Guidance for the First Quarter of 2016	16-04-18	CI
Diadexus, Inc. Announces Preliminary Revenue Results for the First Quarter Ended March 31, 2016	16-04-18	CI
Diadexus, Inc. Announces Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2015	16-03-29	CI
Diadexus, Inc. Auditor Raises 'Going Concern' Doubt	16-03-28	CI
Diadexus, Inc. Announces Resignation of Dr. Emilia Zychlinksy as Executive Vice President and Chief Technical Officer, Effective as of April 1, 2016	16-03-18	CI
Diadexus, Inc. Presents New Plac(r) Activity Data from the Regards Study at 2015 American Heart Association Scientific Sessions	15-11-10	CI
Diadexus, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	15-10-26	CI
Diadexus, Inc. Names Jonathan Ruais as Vice President of Marketing	15-10-13	CI
DiaDexus Signs License Agreement with OriGene Technologies and Wuxi OriGene Biotechnology	15-09-08	CI
Diadexus, Inc. announced that it has received $1 million in funding from OriGene Technologies, Inc..	15-09-03	CI
Transcript : Diadexus, Inc., Q2 2015 Earnings Call, Aug 13, 2015	15-08-13
Diadexus, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015; Rescinds Revenue Guidance for 2015	15-08-13	CI

Chart Diadexus, Inc.

Duration

Period

More charts

Company Profile

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Sector

Pharmaceuticals

More about the company